Fujirebio and Sysmex Expand CDMO Partnership into the Field of Neurodegenerative Diseases under Their Immunoassay Collaboration
![](https://mms.businesswire.com/media/20231129527249/en/1955275/4/FUJIREBIO_-_standard_logo_JPG.jpg)
Fujirebio Holdings, Inc. (President & CEO: Goki Ishikawa) and Sysmex Corporation (President: Kaoru Asano) today announced that they have entered into an agreement to expand their Contract Development and Manufacturing Organization (CDMO) partnership for Sysmex's Automated Immunoassay System HISCL™-Series to include the field of neurodegenerative diseases, following the discussion based on the Basic Agreement on Business Collaboration in the field of immunoassay signed in October 2023*.